Form 4: Novavax CSO Elaine O'Hara Reports Equity Transactions

Novavax's Chief Strategy Officer, Elaine O'Hara, reported the vesting and acquisition of restricted stock units and a new grant of stock options.

Summary

• Elaine O'Hara, EVP, Chief Strategy Officer of Novavax Inc. (NVAX), reported multiple equity transactions on March 1 and March 2, 2026.
• On March 1, 2026, 19,600 Restricted Stock Units (RSUs) from a March 1, 2023 grant vested and converted into common stock.
• Concurrently on March 1, 2026, 5,375 shares of common stock were withheld by the company at a price of $10.14 per share to cover tax withholding obligations related to the RSU vesting.
• Also on March 1, 2026, 40,000 RSUs from a March 1, 2024 grant vested and converted into common stock.
• An additional 10,969 shares of common stock were withheld by the company at $10.14 per share on March 1, 2026, for tax withholding related to the second RSU vesting event.
• On March 2, 2026, O'Hara was granted 118,000 new Restricted Stock Units, which will vest one-third annually over three years starting March 2, 2026.
• Also on March 2, 2026, O'Hara received a grant of 177,500 non-statutory stock options with an exercise price of $9.09 per share. These options will vest one-quarter on the first anniversary of the grant date, with the remainder vesting monthly over the subsequent three years.
• Following these transactions, O'Hara directly beneficially owns 100,737 shares of common stock, 118,000 Restricted Stock Units, and 177,500 non-statutory stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation, reflecting ongoing incentive alignment with company performance through equity grants and vesting.

Positives

• Grant of 118,000 new Restricted Stock Units on March 2, 2026, aligning executive interests with long-term company performance.
• Grant of 177,500 non-statutory stock options with an exercise price of $9.09 on March 2, 2026, providing further incentive for future stock price appreciation.
• Vesting of 59,600 Restricted Stock Units (19,600 from 2023 grant and 40,000 from 2024 grant) on March 1, 2026, indicating the realization of previously awarded equity compensation.

Negatives

• Disposition of 16,344 shares of common stock (5,375 + 10,969) at $10.14 per share to satisfy tax withholding obligations, reducing direct common stock holdings.

Future Outlook

The 118,000 new Restricted Stock Units will vest one-third annually on the first three anniversaries of March 2, 2026, subject to continued employment. The 177,500 non-statutory stock options will vest one-quarter on the first anniversary of March 2, 2026, with the remaining three-quarters vesting in equal monthly installments over the subsequent three years, also subject to continued employment.

Industry Context

StockSavvy.ai notes that equity compensation, including Restricted Stock Units and stock options, is a standard practice for retaining and incentivizing executives in the biotech and pharmaceutical industry, aligning their interests with long-term company performance.

Stakeholder Impact

• Shareholders: The grants of new equity compensation could lead to future share dilution but also align executive incentives with long-term shareholder value creation.
• Employees (specifically Elaine O'Hara): Continued and new equity compensation provides significant financial incentives and retention mechanisms.

Next Steps

• Future vesting of 118,000 Restricted Stock Units on the first three anniversaries of March 2, 2026.
• Future vesting of 177,500 non-statutory stock options, with one-quarter vesting on the first anniversary of March 2, 2026, and the remainder monthly over the subsequent three years.

Key Dates

Keywords

Novavax, NVAX, Form 4, insider trading, stock options, restricted stock units, equity compensation, Elaine O'Hara, Chief Strategy Officer